Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
Express Scripts
Medtronic
AstraZeneca

Last Updated: November 29, 2022

Panobinostat lactate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for panobinostat lactate and what is the scope of freedom to operate?

Panobinostat lactate is the generic ingredient in one branded drug marketed by Secura and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Panobinostat lactate has sixty-seven patent family members in forty countries.

There is one drug master file entry for panobinostat lactate. One supplier is listed for this compound.

Recent Clinical Trials for panobinostat lactate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Abdullah KhanPhase 1

See all panobinostat lactate clinical trials

Pharmacology for panobinostat lactate

US Patents and Regulatory Information for panobinostat lactate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-001 Feb 23, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-003 Feb 23, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-001 Feb 23, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-003 Feb 23, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-002 Feb 23, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for panobinostat lactate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-002 Feb 23, 2015 See Plans and Pricing See Plans and Pricing
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-001 Feb 23, 2015 See Plans and Pricing See Plans and Pricing
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-002 Feb 23, 2015 See Plans and Pricing See Plans and Pricing
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-003 Feb 23, 2015 See Plans and Pricing See Plans and Pricing
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-003 Feb 23, 2015 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for panobinostat lactate

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2007146716 See Plans and Pricing
South Korea 20080031937 USE OF HDAC INHIBITORS FOR THE TREATMENT OF MYELOMA See Plans and Pricing
Japan 2013173757 USE OF HDAC INHIBITOR FOR TREATMENT OF MYELOMA See Plans and Pricing
Lithuania C1912640 See Plans and Pricing
South Korea 101354237 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for panobinostat lactate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1318980 CA 2015 00068 Denmark See Plans and Pricing PRODUCT NAME: PANOBINOSTAT ELLER ET FARMACEUTISK SALT ELLER DERIVAT DERAF; REG. NO/DATE: EU/1/15/1023 20150901
1318980 C01318980/01 Switzerland See Plans and Pricing PRODUCT NAME: PANOBINOSTAT; REGISTRATION NO/DATE: SWISSMEDIC 61878 23.12.2015
1912640 PA2016003,C1912640 Lithuania See Plans and Pricing PRODUCT NAME: PANOBINOSTATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/1023 20120828
1318980 72/2015 Austria See Plans and Pricing PRODUCT NAME: PANOBINOSTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1023 (MITTEILUNG) 20150901
1318980 15C0086 France See Plans and Pricing PRODUCT NAME: PANOBINOSTAT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/1023 20150901
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Moodys
Express Scripts
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.